Cell Biotech Balance Sheet Health
Financial Health criteria checks 6/6
Cell Biotech has a total shareholder equity of ₩115.8B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩122.5B and ₩6.7B respectively. Cell Biotech's EBIT is ₩7.8B making its interest coverage ratio -2.6. It has cash and short-term investments of ₩78.1B.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | -2.6x |
| Cash | ₩78.14b |
| Equity | ₩115.82b |
| Total liabilities | ₩6.71b |
| Total assets | ₩122.53b |
Recent financial health updates
No updates
Recent updates
Shareholders Will Be Pleased With The Quality of Cell Biotech's (KOSDAQ:049960) Earnings
Aug 24
Factors Income Investors Should Consider Before Adding Cell Biotech Co., Ltd. (KOSDAQ:049960) To Their Portfolio
May 05Is Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Recent Price Movement Underpinned By Its Weak Fundamentals?
Mar 18A Look At Cell Biotech's (KOSDAQ:049960) Share Price Returns
Feb 25Key Things To Watch Out For If You Are After Cell Biotech Co., Ltd.'s (KOSDAQ:049960) 3.2% Dividend
Feb 04
Is Cell Biotech Co., Ltd. (KOSDAQ:049960) Popular Amongst Insiders?
Jan 14Don't Race Out To Buy Cell Biotech Co., Ltd. (KOSDAQ:049960) Just Because It's Going Ex-Dividend
Dec 24Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Dec 13Reflecting on Cell Biotech's (KOSDAQ:049960) Share Price Returns Over The Last Five Years
Nov 18Financial Position Analysis
Short Term Liabilities: A049960's short term assets (₩87.9B) exceed its short term liabilities (₩6.0B).
Long Term Liabilities: A049960's short term assets (₩87.9B) exceed its long term liabilities (₩673.7M).
Debt to Equity History and Analysis
Debt Level: A049960 is debt free.
Reducing Debt: A049960 has not had any debt for past 5 years.
Debt Coverage: A049960 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: A049960 has no debt, therefore coverage of interest payments is not a concern.